RECURSION PHARMACEUTICALS, INC. (RXRX) Current Ratio
- Current ratio · latest quarter: Value 5.03×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.03× | Current assets / current liabilities. $603.46M ÷ $119.89M ≈ 5.03× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 603.46M USD | Assets, Current |
| Current obligations | 119.89M USD | Liabilities, Current |
| Cash and equivalents | 545.68M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 12.67M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $603.46M | $119.89M | $545.68M | (m) | (m) | (m) | $12.67M | (m) | 5.03× |
| 2026-03-31 | $709.56M | $129.70M | $654.47M | (m) | (m) | (m) | $20.35M | (m) | 5.47× |
| 2025-12-31 | $812.85M | $147.71M | $743.29M | (m) | (m) | (m) | $18.12M | (m) | 5.50× |
| 2025-09-30 | $714.11M | $155.10M | $659.84M | (m) | (m) | (m) | $13.94M | (m) | 4.60× |
| 2025-06-30 | $587.16M | $164.03M | $525.11M | (m) | (m) | (m) | $19.31M | (m) | 3.58× |
| 2025-03-31 | $584.14M | $141.98M | $500.45M | (m) | (m) | (m) | $25.09M | (m) | 4.11× |
| 2024-12-31 | $714.27M | $187.47M | $594.35M | (m) | (m) | (m) | $21.61M | (m) | 3.81× |
| 2024-09-30 | $474.17M | $108.89M | $427.65M | (m) | (m) | (m) | $2.26M | (m) | 4.35× |
| 2024-06-30 | $522.38M | $86.08M | $474.34M | (m) | (m) | (m) | $3.76M | (m) | 6.07× |
| 2024-03-31 | $343.62M | $73.92M | $296.33M | (m) | (m) | (m) | $5.12M | (m) | 4.65× |
| 2023-12-31 | $438.14M | $93.17M | $391.56M | (m) | (m) | (m) | $3.95M | (m) | 4.70× |
| 2023-09-30 | $410.52M | $94.12M | $387.32M | (m) | (m) | (m) | $4.26M | (m) | 4.36× |
| 2023-06-30 | $431.02M | $113.96M | $405.87M | (m) | (m) | (m) | $2.09M | (m) | 3.78× |
| 2023-03-31 | $492.13M | $92.15M | $473.14M | (m) | (m) | (m) | $4.25M | (m) | 5.34× |
| 2022-12-31 | $569.81M | $100.27M | $549.91M | (m) | (m) | (m) | $4.59M | (m) | 5.68× |
| 2022-09-30 | $481.62M | $83.04M | $454.65M | (m) | $0.00 | (m) | $3.89M | (m) | 5.80× |
| 2022-06-30 | $546.00M | $96.65M | $453.88M | (m) | $21.00K | (m) | $3.18M | (m) | 5.65× |
| 2022-03-31 | $619.46M | $85.70M | $507.89M | (m) | $34.00K | (m) | $4.16M | (m) | 7.23× |
| 2021-12-31 | $534.72M | $46.66M | $285.12M | (m) | $34.00K | (m) | $2.82M | (m) | 11.46× |
| 2021-09-30 | $600.87M | $42.94M | $394.72M | (m) | $34.00K | (m) | $6.33M | (m) | 13.99× |
| 2021-06-30 | $647.63M | $29.54M | $632.74M | (m) | $49.00K | (m) | $3.20M | (m) | 21.92× |
| 2021-03-31 | $221.82M | $26.85M | $214.09M | (m) | $71.00K | (m) | $3.13M | (m) | 8.26× |
| 2020-12-31 | $266.44M | $23.10M | $262.13M | (m) | $156.00K | (m) | $1.07M | (m) | 11.53× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |